The latest price target for Kronos Bio (NASDAQ:KRON) was reported by HC Wainwright & Co. on August 19, 2024. The analyst firm set a price target for $2.25 expecting KRON to rise to within 12 months (a possible 118.45% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Kronos Bio (NASDAQ:KRON) was provided by HC Wainwright & Co., and Kronos Bio reiterated their buy rating.

There is no last upgrade for Kronos Bio

There is no last downgrade for Kronos Bio.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kronos Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kronos Bio was filed on August 19, 2024 so you should expect the next rating to be made available sometime around August 19, 2025.

While ratings are subjective and will change, the latest Kronos Bio (KRON) rating was a reiterated with a price target of $2.25 to $2.25. The current price Kronos Bio (KRON) is trading at is $1.03, which is out of the analyst’s predicted range.